Recent Price Movement and Market Context
The stock has underperformed notably, falling by 6.41% on the day and underperforming its sector by 6.25%. Over the last two trading sessions, Piramal Pharma has recorded a cumulative decline of 6.56%, with the intraday low touching Rs 144.85, down 6.7% from previous levels. The share price currently trades below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a sustained bearish momentum.
On the broader market front, the Nifty index closed at 23,639.15, down 0.95% or 227.7 points, continuing a three-week losing streak with a cumulative fall of 7.56%. Several indices, including the S&P Bse Dollex 30, S&P Bse Teck, and S&P Bse FMCG, also hit new 52-week lows on the same day, reflecting a challenging environment across sectors. All market capitalisation segments experienced declines, with Mega Caps exerting downward pressure on the Nifty 50 index.
Financial Performance and Profitability Concerns
Piramal Pharma’s financial metrics reveal ongoing difficulties. The company has reported negative results for three consecutive quarters, with the latest quarter showing a Profit Before Tax (excluding other income) of Rs -95.99 crores, a steep decline of 2,577.2% compared to the previous four-quarter average. The net profit after tax (PAT) also fell sharply by 755.0% to Rs -95.08 crores, with earnings per share (EPS) at a low of Rs -1.03.
These figures highlight a significant contraction in profitability, which has contributed to the stock’s weak performance. Over the past year, Piramal Pharma’s profits have declined by 372.9%, while the stock itself has generated a negative return of 27.80%, contrasting with the BSE500 index’s positive return of 7.46% over the same period.
Under the radar no more! This Large Cap from Cement is emerging from turnaround with solid fundamentals intact. Discover it while it's still relatively hidden!
- - Hidden turnaround gem
- - Solid fundamentals confirmed
- - Large Cap opportunity
Debt Levels and Growth Metrics
The company’s ability to service its debt remains constrained, with a high Debt to EBITDA ratio of 3.83 times. This elevated leverage ratio indicates a substantial debt burden relative to earnings before interest, taxes, depreciation, and amortisation. Despite this, the company has demonstrated a modest long-term sales growth rate of 7.96% annually over the past five years.
Return on Equity (ROE) has been notably low, averaging 0.32%, which suggests limited profitability generated per unit of shareholders’ funds. However, operating profit has shown a robust annual growth rate of 111.53%, indicating some operational efficiency improvements despite the overall financial strain.
Valuation and Institutional Holdings
Piramal Pharma’s Return on Capital Employed (ROCE) stands at 2.7%, with an enterprise value to capital employed ratio of 2, reflecting a fair valuation relative to its capital base. The stock is trading at a discount compared to its peers’ historical average valuations, which may be a factor in its current market price.
Institutional investors hold a significant stake of 45.35% in the company, suggesting that entities with greater analytical resources maintain exposure despite recent performance trends.
Technical Indicators and Market Sentiment
Technical analysis presents a predominantly bearish outlook. The Moving Average Convergence Divergence (MACD) indicator is bearish on a weekly basis and mildly bearish monthly. Bollinger Bands signal mild bearishness weekly and bearishness monthly. The daily moving averages also reflect a bearish trend. Other indicators such as the KST and Dow Theory are mildly bearish weekly and monthly, while the On-Balance Volume (OBV) shows mild bearishness weekly with no clear monthly trend. The Relative Strength Index (RSI) does not currently signal any definitive trend on weekly or monthly charts.
Is Piramal Pharma Ltd your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Comparative Performance and Market Capitalisation
Over the last year, Piramal Pharma’s stock has declined by 27.80%, a stark contrast to the Sensex’s positive 2.71% return. The stock is classified as a small-cap with a Mojo Score of 26.0 and a Mojo Grade of Strong Sell, upgraded from Sell on 18 Feb 2026. This grading reflects the company’s challenges in growth and profitability, as well as its debt servicing capacity.
The 52-week high for the stock was Rs 240.95, indicating a substantial decline from its peak price. The current market environment, combined with the company’s financial metrics, has contributed to this downward pressure.
Summary of Key Metrics
To summarise, Piramal Pharma Ltd’s stock is trading near its 52-week low of Rs 142.95, with recent prices around Rs 144.85. The stock has underperformed both its sector and broader market indices, with negative returns and declining profitability. High leverage, low ROE, and consecutive quarterly losses have weighed on investor sentiment. Technical indicators predominantly signal bearish trends, while institutional holdings remain significant.
Despite some positive signs such as healthy operating profit growth and fair valuation metrics, the overall picture remains subdued as reflected in the stock’s recent price action and financial disclosures.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
